$2.48
2.27% today
NYSE, Feb 28, 05:22 pm CET
ISIN
US74168J1016
Symbol
PRME
Sector
Industry

Prime Medicine Stock price

$2.42
-0.61 20.13% 1M
-1.89 43.85% 6M
-0.50 17.12% YTD
-6.97 74.23% 1Y
-14.58 85.76% 3Y
-14.58 85.76% 5Y
-14.58 85.76% 10Y
NYSE, Closing price Thu, Feb 27 2025
-0.12 4.72%
ISIN
US74168J1016
Symbol
PRME
Sector
Industry

Key metrics

Market capitalization $317.41m
Enterprise Value $183.13m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 228.91
P/S ratio (TTM) P/S ratio 396.76
P/B ratio (TTM) P/B ratio 1.67
Revenue (TTM) Revenue $800.00k
EBIT (operating result TTM) EBIT $-212.79m
Free Cash Flow (TTM) Free Cash Flow $-190.32m
Cash position $175.53m
EPS (TTM) EPS $-2.01
P/E forward negative
P/S forward 27.48
EV/Sales forward 15.86
Short interest 26.46%
Show more

Is Prime Medicine a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,809 stocks worldwide.

Prime Medicine Stock Analysis

Unlock Scores for Free

Analyst Opinions

10 Analysts have issued a Prime Medicine forecast:

9x Buy
90%
1x Hold
10%

Analyst Opinions

10 Analysts have issued a Prime Medicine forecast:

Buy
90%
Hold
10%

Financial data from Prime Medicine

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
0.80 0.80
-
100%
- Direct Costs 5.66 5.66
66% 66%
708%
-4.86 -4.86
71% 71%
-608%
- Selling and Administrative Expenses 40 40
474% 474%
4,954%
- Research and Development Expense 163 163
20% 20%
20,330%
-207 -207
30% 30%
-25,891%
- Depreciation and Amortization 5.66 5.66
66% 66%
708%
EBIT (Operating Income) EBIT -213 -213
21% 21%
-26,599%
Net Profit -219 -219
28% 28%
-27,406%

In millions USD.

Don't miss a Thing! We will send you all news about Prime Medicine directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Prime Medicine Stock News

Neutral
GlobeNewsWire
about 4 hours ago
-- On track to report initial data from Phase 1/2 clinical trial of PM359 for p47 phox CGD in 2025 -- -- IND-enabling studies ongoing for PM577 for Wilson's Disease; expect to file IND and/or CTA in 1H 2026 -- -- Additional high-value programs advancing through preclinical development -- CAMBRIDGE, Mass., Feb. 28, 2025 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology com...
Neutral
GlobeNewsWire
4 days ago
CAMBRIDGE, Mass. , Feb. 24, 2025 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today announced that Keith Gottesdiener, M.D.
Neutral
PRNewsWire
29 days ago
NEW YORK , Jan. 30, 2025 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Prime Medicine, Inc. (NASDAQ: PRME) breached their fiduciary duties to shareholders. The investigation concerns potential self-dealing.
More Prime Medicine News

Company Profile

Prime Medicine, Inc. is a biotechnology company, which engages in developing one-time curative genetic therapies. The company was founded by David R. Liu on September 13, 2019 and is headquartered in Cambridge, MA.

Head office United States
CEO Keith Gottesdiener
Employees 234
Founded 2019
Website www.primemedicine.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today